Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients
Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC.
(WRAL Tech Wire)
Related: Campus Connections
New ESPN documentary to highlight Stuart Scott’s life, legacyThe phrase “boo-yah” did not enter the lexicon without resistance. At a time when the sports broadcasting vernacular was bound by the constraints of Merriam...
Fri Nov 28, 2025THT Newsletter: UNC Basketball Feast Week, Football 'Flip Season,' Dylan Mingo Trims List
Happy Thanksgiving! I hope you’re enjoying some well-earned down time with friends, food, family, and Tar Heel sports. This weekend, we’ve got men’s and women’s...
Thu Nov 27, 2025
Pantry Bowl 2025 combats campus hunger
UNC and NC State will again come together on something both can agree on — making sure no student goes to class hungry. The fifth...
Tue Nov 25, 2025
How UNC superfan, Randall Keen, rallies in Carolina blue
Living with ALS hasn’t stopped 64-year-old Randall Keen from cheering for nearly every Tar Heel team — or from teaching his daughter, Avery, what it...
Tue Nov 25, 2025